Document Detail

Imatinib assay by high-performance liquid chromatography in tandem mass spectrometry with solid-phase extraction in human plasma.
MedLine Citation:
PMID:  23034891     Owner:  NLM     Status:  MEDLINE    
We have developed a method of liquid chromatography in tandem with mass spectrometry to monitor therapeutic levels of imatinib in plasma, a selective inhibitor of protein tyrosine kinase. After solid-phase extraction of plasma samples, imatinib and its internal standard, imatinib-D8, were eluted with Zorbax SB-C18 at 60 °C, under isocratic conditions through a mobile phase consisting of 4 mm ammonium formate, pH: 3.2 (solution A) and acetonitrile solution B. The flow rate was 0.8 mL/min with 55% solution A + 45% solution B. Imatinib was detected and quantified by mass spectrometry with electrospray ionization operating in selected-reaction monitoring mode. The calibration curve was linear in the range 10-5000 ng/mL, the lower limit of quantitation being 10 ng/mL. The method was validated according to the recommendations of the Food and Drug Administration, including tests of matrix effect (bias < 10%) and recovery efficiency (>80 and <120%). The method is precise (coefficient of variance intra-day <2% and inter-day <7%), accurate (95-108%), sensitive and specific. It is a simple method with very fast recording time (1.2 min) that is applicable to clinical practice. This will permit improvement of the pharmacological treatment of patients.
Jose María Moreno; Aneta Wojnicz; Juan Luis Steegman; Maria F Cano-Abad; Ana Ruiz-Nuño
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't; Validation Studies     Date:  2012-10-04
Journal Detail:
Title:  Biomedical chromatography : BMC     Volume:  27     ISSN:  1099-0801     ISO Abbreviation:  Biomed. Chromatogr.     Publication Date:  2013 Apr 
Date Detail:
Created Date:  2013-03-06     Completed Date:  2013-08-21     Revised Date:  2013-08-26    
Medline Journal Info:
Nlm Unique ID:  8610241     Medline TA:  Biomed Chromatogr     Country:  England    
Other Details:
Languages:  eng     Pagination:  502-8     Citation Subset:  IM    
Copyright Information:
Copyright © 2012 John Wiley & Sons, Ltd.
Instituto Teófilo Hernando, Facultad de Medicina, Universidad Autónoma de Madrid, Madrid, Spain.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Antineoplastic Agents / blood*
Benzamides / blood*
Chromatography, High Pressure Liquid / methods*
Drug Monitoring / methods
Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy
Limit of Detection
Piperazines / blood*
Protein Kinase Inhibitors / blood*
Pyrimidines / blood*
Solid Phase Extraction / methods*
Tandem Mass Spectrometry / methods*
Reg. No./Substance:
0/Antineoplastic Agents; 0/Benzamides; 0/Piperazines; 0/Protein Kinase Inhibitors; 0/Pyrimidines; BKJ8M8G5HI/imatinib

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Germline variation in TP53 regulatory network genes associates with breast cancer survival and treat...
Next Document:  Maximum Likelihood Pedigree Reconstruction Using Integer Linear Programming.